Importantly, we confirmed that thymidylate synthase inhibition with raltitrexed in vivo in a prostate cancer xenograft could decrease Survivin and sensitize to navitoclax, with the combination causing marked and persistent tumor regression. The gene discussed is BIRC5; the disease is prostate cancer.